Investigating a key pathway involved in diabetes complications
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis
This study is looking at how a substance called 3-deoxyglucosone (3DG) affects people with diabetes, especially in causing kidney problems, and it's using mice to find out more about it so that new treatments can be developed to help manage diabetes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lankenau Institute for Medical Research NIH-funded |
| Lab location | 1 site (Wynnewood, United States) |
| Project ID | NIH-10766705 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific compound, 3-deoxyglucosone (3DG), contributes to diabetes complications by damaging cells and inflaming blood vessels. The study aims to measure the levels of 3DG in tissues and explore its relationship with diabetic nephropathy using a mouse model of type-2 diabetes. Researchers are also developing new methods to study an enzyme that may help repair damaged proteins but also produces 3DG. By uncovering these mechanisms, the research seeks to identify potential therapeutic targets for improving diabetes management.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type-2 diabetes, particularly those experiencing complications such as diabetic nephropathy.
Not a fit: Patients without diabetes or those with type-1 diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments that reduce complications associated with diabetes.
How similar studies have performed: Previous research has shown promising results in understanding the role of advanced glycation end products in diabetes, suggesting that this approach could yield valuable insights.
Where this research is happening
Wynnewood, United States
- Lankenau Institute for Medical Research — Wynnewood, United States (Active)
Researchers
- Principal investigator: Prendergast, George C — Lankenau Institute for Medical Research
- Study coordinator: Prendergast, George C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.